Scienture (NASDAQ:SCNX) Raised to Hold at Wall Street Zen

Scienture (NASDAQ:SCNX) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Several other analysts also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a research note on Monday, December 29th. Maxim Group began coverage on Scienture in a research note on Tuesday, February 24th. They set a “buy” rating and a $1.50 price target on the stock. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $1.50.

Scienture Trading Down 8.4%

SCNX opened at $0.47 on Friday. The company has a fifty day moving average price of $0.46 and a two-hundred day moving average price of $0.65. Scienture has a 1-year low of $0.37 and a 1-year high of $3.17. The company has a market cap of $18.99 million, a P/E ratio of -0.47 and a beta of 3.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Scienture stock. Virtu Financial LLC bought a new stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned about 0.22% of Scienture as of its most recent SEC filing. 5.68% of the stock is currently owned by institutional investors.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.